SHANGHAI, June 15,
2023 /PRNewswire/ -- 111, Inc. ("111" or the
"Company") (NASDAQ: YI), a leading tech-enabled healthcare platform
company committed to digitally connecting patients with medicine
and healthcare services in China,
today announced its unaudited financial results for the first
quarter ended March 31, 2023.
First Quarter 2023 Highlights
- Net revenues were RMB3.7
billion (US$538.3 million),
representing an increase of 23.9% year-over-year.
- Gross segment profit (1) increased by
22.7% year-over-year, with B2B segment profit increasing by 25.5%
year-over-year.
- Total operating expenses were RMB257.9 million (US$37.6
million), compared to RMB294.7
million in the same quarter of last year. As a
percentage of net revenues, total operating expenses decreased to
7.0% from 9.9% in the same quarter of last year, which reflected
continuous improvement in our operation efficiency.
- Loss from operations was RMB21.7 million (US$3.2
million), compared to RMB102.2
million in the same quarter of last year. As a percentage of
net revenues, loss from operations decreased to 0.6% from 3.4% in
the same quarter of last year.
- Non-GAAP income from
operations (2) was RMB2.5
million (US$0.4 million),
compared to Non-GAAP loss from operations was RMB72.4
million in the same quarter of last year.
(1) Gross segment profit represents net
revenues less cost of goods sold.
(2)
Non-GAAP income from operations represents income from
operations excluding share-based compensation expenses.
Mr. Junling Liu, Co-Founder,
Chairman, and Chief Executive Officer of 111, commented, "We are
pleased to report another solid quarter as well as a positive
operating results at Non-GAAP level. Net revenue increased by
23.9% year-over-year to RMB3.7
billion, marking the 19th consecutive quarter of
year-over-year growth for 111 since the company's NASDAQ IPO.
Our gross segment profit for the quarter increased by 22.7%
year-over-year. As a result, loss from operation decreased to
RMB22 million compared to
RMB102 million in the same quarter of
last year. Non-GAAP operating profit for the quarter turned
positive as compared to a Non-GAAP loss from operations in the same
quarter of last year, which partially benefited from the lifting of
COVID-related restrictions since December last year."
Mr. Liu added, "In addition, we continued to enhance our
operation efficiency and total operating expenses as a percentage
of net revenues decreased to 7.0% in this quarter from 9.9% in the
same quarter of last year. We expect this momentum to
continue as we scale, and meanwhile we will continue to focus on
delivering best services to our customers/patients."
"These results stem from our sustained, strategic endeavors. We
have enhanced partnerships with upstream pharmaceutical partners.
By directly working with 500+ pharmaceutical companies, we offer
value-add services to numerous enterprises, debuted products like
Sanofi's Allegra on our B2C platform, while our B2B platform's
digital marketing tool, "Telescope," offers invaluable market
insights. Our digital empowerment to downstream pharmacies provided
them with cost-effective products and operational efficiency. By
the end of Q1, we served more than 435,000 retail pharmacies, with
our 1 Health program engaging approximately 20,000 drugstores.
Meanwhile, our operational efficiency continues to improve with
various cost saving initiatives, better corporate governance, and
technology investments. We've notably cut fulfillment costs through
optimizing our own and joint-venture warehouses, while our new
advisory department, focused on customer-centric value creation, is
refining product assortment and pricing strategies."
"We believe that our efforts to achieve margin expansion, as
well as to optimize our cost and improve our organizational
alignment, have delivered positive results. We will keep
optimizing product assortment based on customer needs, reducing
costs with direct sourcing, and improve our competitiveness through
intelligent pricing. We will keep improving efficiency through
supply chain optimization and we will continually commit to
digitization to enhance processes and drive innovation. We are
confident that our strong technology capabilities will continue to
enable us to build scale, deliver profitability, and maximize
values for our shareholders."
First Quarter 2023 Financial Results
Net revenues were RMB3.7
billion (US$538.3 million),
representing an increase of 23.9% from RMB3.0 billion in
the same quarter of last year.
(In thousands
RMB)
|
For the three months
ended March 31,
|
|
|
|
|
|
|
|
2022
|
|
2023
|
|
YoY
|
B2B Net Revenue
|
|
|
|
|
|
Product
|
2,851,396
|
|
3,562,682
|
|
24.9 %
|
Service
|
18,360
|
|
21,141
|
|
15.1 %
|
|
|
|
|
|
|
Sub-Total
|
2,869,756
|
|
3,583,823
|
|
24.9 %
|
|
|
|
|
|
|
Cost of Products
Sold(3)
|
2,701,643
|
|
3,372,828
|
|
24.8 %
|
|
|
|
|
|
|
Segment Profit
|
168,113
|
|
210,995
|
|
25.5 %
|
Segment Profit %
|
5.9 %
|
|
5.9 %
|
|
|
(In thousands
RMB)
|
For the three months
ended March 31,
|
|
|
|
|
|
|
|
2022
|
|
2023
|
|
YoY
|
B2C Net Revenue
|
|
|
|
|
|
Product
|
102,131
|
|
106,608
|
|
4.4 %
|
Service
|
10,704
|
|
6,330
|
|
-40.9 %
|
|
|
|
|
|
|
Sub-Total
|
112,835
|
|
112,938
|
|
0.1 %
|
|
|
|
|
|
|
Cost of Products
Sold
|
88,413
|
|
87,720
|
|
-0.8 %
|
|
|
|
|
|
|
Segment Profit
|
24,422
|
|
25,218
|
|
3.3 %
|
Segment Profit %
|
21.6 %
|
|
22.3 %
|
|
|
(3) For segment reporting purposes, purchase rebates are
allocated to the B2B segment and B2C segments primarily based on
the amount of cost of products sold for each segment. Cost of
products sold does not include other direct costs related to cost
of product sales such as shipping and handling expense, payroll and
benefits of logistic staff, logistic centers rental expenses and
depreciation expenses, which are recorded in the fulfillment
expenses. Cost of service revenue is recorded in the operating
expense.
Operating costs and expenses were RMB3.7
billion (US$541.5 million),
representing an increase of 20.5% from RMB3.1 billion in
the same quarter of last year.
- Cost of products sold was RMB3.5
billion (US$503.9 million),
representing an increase of 24.0% from RMB2.8 billion in
the same quarter of last year. The increase was primarily due to
our revenue growth in B2B business, which increased by 24.9% from
the same quarter last year.
- Fulfillment expenses were RMB102.7
million (US$14.9 million),
representing an increase of 8.6% from RMB94.5 million in
the same quarter of last year. Fulfillment expenses accounted for
2.8% of net revenues this quarter as compared to 3.2% in the same
quarter of last year.
- Selling and marketing expenses were RMB89.2
million (US$13.0 million),
representing a decrease of 22.3% from RMB114.9 million in
the same quarter of last year. Excluding the share-based
compensation expenses of RMB1.1
million for the quarter and RMB8.4
million for the same quarter last year, respectively,
selling and marketing expenses as a percentage of net revenues,
accounted for 2.4% in the quarter as compared to 3.6% in the same
quarter of last year.
- General and administrative
expenses were RMB41.3 million (US$6.0 million), representing a decrease of 13.9%
from RMB48.0 million in the same quarter of last year.
Excluding the share-based compensation expenses of RMB19.0 million for the quarter and RMB17.7 million for the same quarter last year,
respectively, general and administrative expenses as a percentage
of net revenues, accounted for 0.6% in the quarter as compared to
1.0% in the same quarter of last year.
- Technology expenses were RMB25.3
million (US$3.7 million),
compared with RMB39.0 million in the same quarter of last
year. Excluding the share-based compensation expenses of
RMB4.1 million for the quarter and
RMB3.6 million for the same quarter
last year, respectively, Technology expenses as a percentage of net
revenues, accounted for 0.6% in the quarter as compared to 1.2% in
the same quarter of last year.
Loss from operations was RMB21.7
million (US$3.2 million),
compared to RMB102.2 million in the same quarter of last
year. As a percentage of net revenues, loss from operations
decreased to 0.6% in the quarter from 3.4% in the same quarter of
last year.
Non-GAAP income from operations was RMB2.5
million (US$0.4 million),
compared to Non-GAAP loss from operations was RMB72.4
million in the same quarter of last year.
Net loss was RMB19.4 million (US$2.8 million), compared to RMB101.0
million in the same quarter of last year. As a percentage of
net revenues, net loss decreased to 0.5% in the quarter from 3.4%
in same quarter of last year.
Non-GAAP net income (4) was RMB4.9
million (US$0.7 million),
compared to Non-GAAP net loss was RMB71.2 million in the
same quarter of last year.
Net loss attributable to ordinary
shareholders was RMB31.8 million (US$4.6 million), compared to RMB110.3
million in the same quarter of last year. As a percentage of
net revenues, net loss attributable to ordinary shareholders
decreased to 0.9% in the quarter from 3.7% in same quarter of last
year.
Non-GAAP net loss attributable to ordinary shareholders
(5) was RMB7.6
million (US$1.1 million),
compared to RMB80.6 million in the
same quarter of last year. As a percentage of net revenues,
non-GAAP net loss attributable to ordinary shareholders decreased
to 0.2% in the quarter from 2.7% in same quarter of last year.
(4) Non-GAAP net income represents net income excluding
share-based compensation expenses, net of tax. Considering the
impact of accretion of redeemable non-controlling interest for the
first quarter 2023, non-GAAP net income is used as a more
meaningful measurement of the operation performance of the
Company.
(5) Non-GAAP net loss attributable to
ordinary shareholders represents net loss attributable to ordinary
shareholders excluding share-based compensation expenses, net of
tax.
As of March 31, 2023, the
Company had cash and cash equivalents, restricted cash and
short-term investments of RMB878.8
million (US$128.0 million),
compared to RMB922.7 million as of
December 31, 2022.
Conference Call
111's management team will host an earnings conference call at
7:30 AM U.S. Eastern Time on
Thursday, June 15, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Event Title: 111, Inc. First Quarter 2023 Unaudited Financial
Results
Registration Link:
https://s1.c-conf.com/diamondpass/10030880-st6fye.html
All participants must use the link provided above to complete
the online registration process in advance of the conference call.
Upon registering, each participant will receive a set of
participant dial-in numbers, the Direct Event passcode, and a
unique Registration ID, which can be used to join the conference
call.
Please dial in 15 minutes before the call is scheduled to begin
and provide the Direct Event passcode and unique Registration ID
you have received upon registering to join the call.
A telephone replay of the call will be available after the
conclusion of the conference call until June
22, 2023 on:
Mainland China: 4001 209 217
Hong Kong: 800 901 654
United States: +1 877 642 9125
International: +61 7 3145 4057
Conference ID: 10030880
A live and archived webcast of the conference call will be
available on the website at
https://edge.media-server.com/mmc/p/uzvzjixt.
Use of Non-GAAP Financial Measures
In evaluating the business, the Company considers and uses
non-GAAP income (loss) from operations, non-GAAP net income (loss),
non-GAAP net loss attributable to ordinary shareholders, and
non-GAAP loss per ADS, as supplemental measures to review and
assess its operating performance. The Company defines non-GAAP
income (loss) from operations as income (loss) from operations
excluding share-based compensation expenses. The Company defines
non-GAAP net income (loss) as net income (loss) excluding
share-based compensation expenses, net of tax. The Company defines
non-GAAP net loss attributable to ordinary shareholders as net loss
attributable to ordinary shareholders excluding share-based
compensation expenses, net of tax. The Company defines non-GAAP
loss per ADS as net loss attributable to ordinary shareholders per
ADS excluding share-based compensation expenses, net of tax per
ADS. The presentation of these non-GAAP financial measures is not
intended to be considered in isolation or as a substitute for the
financial information prepared and presented in accordance with
U.S. GAAP.
The Company believes that non-GAAP income (loss) from
operations, non-GAAP net income (loss), non-GAAP net loss
attributable to ordinary shareholders, and non-GAAP loss per ADS
help identify underlying trends in its business that could
otherwise be distorted by the effect of certain expenses that it
includes in income (loss) from operations and net income (loss).
Share-based compensation expenses is a non-cash expense that varies
from period to period. As a result, management excludes the items
from its internal operating forecasts and models. Management
believes that the adjustments for share-based compensation expenses
provide investors with a reasonable basis to measure the company's
core operating performance, in a more meaningful comparison with
the performance of other companies. The Company believes that
non-GAAP income (loss) from operations, non-GAAP net income (loss),
non-GAAP net loss attributable to ordinary shareholders, and
non-GAAP loss per ADS provide useful information about its
operating results, enhances the overall understanding of its past
performance and future prospects and allow for greater visibility
with respect to key metrics used by the management in their
financial and operational decision-making.
The non-GAAP financial measures are not defined under U.S. GAAP
and are not presented in accordance with U.S. GAAP. The non-GAAP
financial measures have limitations as analytical tools. One of the
key limitations of using non-GAAP income (loss) from operations,
non-GAAP net income (loss), non-GAAP net loss attributable to
ordinary shareholders, or non-GAAP loss per ADS is that it does not
reflect all items of income and expense that affect the Company's
operations. Further, the non-GAAP financial measures may differ
from the non-GAAP information used by other companies, including
peer companies, and therefore their comparability may be
limited.
The Company compensates for these limitations by reconciling the
non-GAAP financial measures to the most comparable U.S. GAAP
measures, all of which should be considered when evaluating the
Company's performance. The Company encourages you to review its
financial information in its entirety and not rely on a single
financial measure.
Reconciliation of the non-GAAP financial measures to the most
comparable U.S. GAAP measures is included at the end of this press
release.
Exchange Rate Information Statement
This announcement contains translations of certain RMB amounts
into U.S. dollars at specified rates solely for the convenience of
the reader. Unless otherwise noted, all translations from RMB to
U.S. dollars are made at a rate of RMB6.8676 to US$1.00, the exchange rate set forth in the H.10
statistical release of the Board of Governors of the Federal
Reserve System as of March 31,
2023.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates," "target,"
"confident" and similar statements. Among other things, the
Business Outlook and quotations from management in this
announcement, as well as 111's strategic and operational plans,
contain forward-looking statements. 111 may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Such statements are based upon management's current
expectations and current market and operating conditions and relate
to events that involve known or unknown risks, uncertainties and
other factors, all of which are difficult to predict and many of
which are beyond the Company's control. Forward-looking statements
involve inherent risks, uncertainties and other factors that could
cause actual results to differ materially from those contained in
any such statements. Potential risks and uncertainties include, but
are not limited to, uncertainties as to the Company's ability
comply with extensive and evolving regulatory requirements, its
ability to compete effectively in the evolving PRC general health
and wellness market, its ability to manage the growth of its
business and expansion plans, its ability to achieve or maintain
profitability in the future, its ability to control the risks
associated with its pharmaceutical retail and wholesale businesses,
and the Company's ability to meet the standards necessary to
maintain listing of its ADSs on the Nasdaq Global Market, including
its ability to cure any non-compliance with Nasdaq's continued
listing criteria. Further information regarding these and other
risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. All
information provided in this press release is as of the date of
this press release, and 111 does not undertake any obligation to
update any forward-looking statement as a result of new
information, future events or otherwise, except as required under
applicable law.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
tech-enabled healthcare platform company committed to digitally
connecting patients with medicine and healthcare services in
China. The Company provides
consumers with better access to pharmaceutical products and
healthcare services directly through its online retail pharmacy, 1
Pharmacy, and indirectly through its offline virtual pharmacy
network. The Company also offers online healthcare services through
its internet hospital, 1 Clinic, which provides consumers with
cost-effective and convenient online consultation, electronic
prescription service, and patient management service. In addition,
the Company's online platform, 1 Medicine, serves as a one-stop
shop for pharmacies to source a vast selection of pharmaceutical
products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to
better serve their customers with cloud-based services. 111 also
provides an omni-channel drug commercialization platform to its
strategic partners, which includes services such as digital
marketing, patient education, data analytics, and pricing
monitoring.
For more information on 111, please visit:
http://ir.111.com.cn/.
111,
Inc.
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS
(In thousands,
except for share and per share data)
|
|
As of
|
As of
|
|
December 31,
2022
|
March 31,
2023
|
|
RMB
|
|
|
RMB
|
|
US$
|
ASSETS
|
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
673,669
|
|
|
584,544
|
|
85,116
|
Restricted
cash
|
43,122
|
|
|
34,737
|
|
5,058
|
Short-term
investments
|
205,861
|
|
|
259,498
|
|
37,786
|
Accounts receivable,
net
|
488,875
|
|
|
437,288
|
|
63,674
|
Notes
Receivable
|
43,332
|
|
|
43,704
|
|
6,364
|
Inventories
|
1,498,900
|
|
|
1,468,172
|
|
213,782
|
Prepayments and other
current assets
|
282,066
|
|
|
191,720
|
|
27,916
|
Total current
assets
|
3,235,825
|
|
|
3,019,663
|
|
439,696
|
Property and equipment,
net
|
48,497
|
|
|
44,809
|
|
6,525
|
Intangible assets,
net
|
3,267
|
|
|
2,871
|
|
418
|
Long-term
investments
|
2,000
|
|
|
2,000
|
|
291
|
Other non-current
assets
|
20,348
|
|
|
20,195
|
|
2,941
|
Operating
lease right-of-use asset
|
163,877
|
|
|
149,275
|
|
21,736
|
Total
Assets
|
3,473,814
|
|
|
3,238,813
|
|
471,607
|
|
|
|
|
|
|
|
LIABILITIES,
MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT
|
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
|
|
Short-term
borrowings
|
178,990
|
|
|
269,852
|
|
39,293
|
Accounts
payable
|
1,764,849
|
|
|
1,681,293
|
|
244,815
|
Accrued expense and
other current liabilities
|
781,271
|
|
|
550,227
|
|
80,119
|
Total Current
liabilities
|
2,725,110
|
|
|
2,501,372
|
|
364,227
|
Long-term operating
lease liabilities
|
100,469
|
|
|
85,917
|
|
12,510
|
Total
Liabilities
|
2,825,579
|
|
|
2,587,289
|
|
376,737
|
|
|
|
|
|
|
|
MEZZANINE
EQUITY
|
|
|
|
|
|
|
Redeemable
non-controlling interests
|
1,056,939
|
|
|
1,070,769
|
|
155,916
|
|
|
|
|
|
|
|
SHAREHOLDERS'
DEFICIT
|
|
|
|
|
|
|
Ordinary shares Class
A
|
31
|
|
|
31
|
|
5
|
Ordinary shares Class
B
|
25
|
|
|
25
|
|
3
|
Treasury
shares
|
(40,859)
|
|
|
(40,859)
|
|
(5,949)
|
Additional paid-in
capital
|
2,977,174
|
|
|
3,003,037
|
|
437,276
|
Accumulated
deficit
|
(3,426,556)
|
|
|
(3,458,343)
|
|
(503,574)
|
Accumulated other
comprehensive income
|
75,586
|
|
|
72,706
|
|
10,587
|
Total shareholders'
deficit
|
(414,599)
|
|
|
(423,403)
|
|
(61,652)
|
Non-controlling
interest
|
5,895
|
|
|
4,158
|
|
606
|
Total
Deficit
|
(408,704)
|
|
|
(419,245)
|
|
(61,046)
|
Total liabilities,
mezzanine equity and deficit
|
3,473,814
|
|
|
3,238,813
|
|
471,607
|
111,
Inc.
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
|
(In thousands,
except for share and per share data)
|
|
|
For the three months
ended March 31,
|
|
2022
|
2023
|
|
RMB
|
RMB
|
US$
|
Net
Revenues
|
2,982,591
|
3,696,761
|
538,290
|
Operating Costs and
expenses:
|
|
|
|
Cost of products
sold
|
(2,790,056)
|
(3,460,548)
|
(503,895)
|
Fulfillment
expenses
|
(94,533)
|
(102,650)
|
(14,947)
|
Selling and
marketing expenses
|
(114,854)
|
(89,240)
|
(12,994)
|
General and
administrative expenses
|
(47,994)
|
(41,317)
|
(6,016)
|
Technology
expenses
|
(39,021)
|
(25,316)
|
(3,686)
|
Other operating
income, net
|
1,716
|
578
|
84
|
Total Operating
costs and expenses
|
(3,084,742)
|
(3,718,493)
|
(541,454)
|
Loss from
operations
|
(102,151)
|
(21,732)
|
(3,164)
|
Interest
income
|
2,043
|
1,949
|
284
|
Interest
expense
|
(3,184)
|
(4,272)
|
(622)
|
Foreign exchange
gain
|
391
|
1,634
|
238
|
Other Income,
net
|
1,913
|
3,064
|
446
|
Loss before income
taxes
|
(100,988)
|
(19,357)
|
(2,818)
|
Income tax
expense
|
-
|
-
|
-
|
Net
Loss
|
(100,988)
|
(19,357)
|
(2,818)
|
Net Loss attributable
to non-controlling interest
|
4,477
|
1,400
|
204
|
Net Loss attributable
to redeemable non-controlling interest
|
9,135
|
1,548
|
225
|
Adjustment attributable
to redeemable non-controlling interest
|
(22,966)
|
(15,378)
|
(2,239)
|
Net Loss
attributable to ordinary shareholders
|
(110,342)
|
(31,787)
|
(4,628)
|
Other comprehensive
loss
|
|
|
|
Unrealized gains
of available-for-sale securities,
|
1,298
|
2,135
|
311
|
Realized gains of
available-for-sale debt securities
|
(1,335)
|
(1,902)
|
(277)
|
Foreign currency
translation adjustments
|
(956)
|
(3,113)
|
(453)
|
Comprehensive
loss
|
(111,335)
|
(34,667)
|
(5,047)
|
Loss per
ADS:
|
|
|
|
Basic and
diluted
|
(1.32)
|
(0.38)
|
(0.06)
|
Weighted average
number of shares used in computation of loss per
share
|
|
|
|
Basic and
diluted
|
166,331,126
|
167,329,609
|
167,329,609
|
111,
Inc.
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(In
thousands)
|
|
|
|
For the three months
ended March 31,
|
|
2022
|
2023
|
|
RMB
|
RMB
|
US$
|
|
|
|
|
Net cash used in
operating activities
|
(68,241)
|
(121,328)
|
(17,668)
|
Net cash provided by
(used in) investing activities
|
22,859
|
(53,188)
|
(7,744)
|
Net cash provided by
financing activities
|
35,278
|
78,497
|
11,430
|
Effect of exchange
rate changes on cash and cash equivalents, and restricted
cash
|
(731)
|
(1,491)
|
(217)
|
Net decrease in cash
and cash equivalents, and restricted cash
|
(10,835)
|
(97,510)
|
(14,199)
|
Cash and cash
equivalents, and restricted cash at the beginning of the
period
|
760,672
|
716,791
|
104,373
|
Cash and cash
equivalents, and restricted cash at the end of the
period
|
749,837
|
619,281
|
90,174
|
111, Inc.
|
Unaudited Reconciliation of GAAP and Non-GAAP
Results
|
(In thousands, except for share and per share
data)
|
|
|
|
|
|
For the three months ended March
31,
|
|
2022
|
2023
|
|
RMB
|
RMB
|
US$
|
|
|
|
|
Loss from
operations
|
(102,151)
|
(21,732)
|
(3,164)
|
Add: Share-based
compensation expenses
|
29,757
|
24,208
|
3,525
|
Non-GAAP income (loss) from
operations
|
(72,394)
|
2,476
|
361
|
|
|
|
|
Net Loss
|
(100,988)
|
(19,357)
|
(2,818)
|
Add: Share-based compensation expenses,
net of tax
|
29,757
|
24,208
|
3,525
|
Non-GAAP net Income (Loss)
|
(71,231)
|
4,851
|
707
|
|
|
|
|
Net Loss attributable to ordinary
shareholders
|
(110,342)
|
(31,787)
|
(4,628)
|
Add: Share-based
compensation expenses, net of tax
|
29,757
|
24,208
|
3,525
|
Non-GAAP net Loss attributable to ordinary
shareholders
|
(80,585)
|
(7,579)
|
(1,103)
|
|
|
|
|
Loss per ADS(6): Basic and
diluted
|
(1.32)
|
(0.38)
|
(0.06)
|
Add: Share-based
compensation expenses per ADS(6), net of tax
|
0.36
|
0.28
|
0.04
|
Non-GAAP Loss per
ADS(6)
|
(0.96)
|
(0.1)
|
(0.02)
|
(6) Every one ADSs represent two Class A ordinary
shares.
View original
content:https://www.prnewswire.com/news-releases/111-inc-announces-first-quarter-2023-unaudited-financial-results-301851656.html
SOURCE 111, Inc.